Fig. 7From: Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review articleRE-DUAL PCI (2017) trial: Primary outcomes of major bleeding were significantly high bleeding in the TAT group compared to both DAT (dabi. 110 and 150 mg). dabi. 110Â mg had a better safety profile (lower bleeding) than TAT and DAT (dabi. 150 mg) [23]. https://doi.org/10.1056/NEJMoa1708454Back to article page